Literature DB >> 7273600

Effect of isoniazid on vitamin D metabolism and hepatic monooxygenase activity.

M J Brodie, A R Boobis, C J Hillyard, G Abeyasekera, I MacIntyre, B K Park.   

Abstract

isoniazid, 300 mg daily for 14 days, reduced serum calcium and phosphate levels (P less than 0.001) in eight healthy subjects. After a single dose of isoniazid the concentration of 1 alpha-,25-dihydroxyvitamin D, the most active metabolite of vitamin D, fell by 47% (P less than 0.01) and was reduced throughout the study. Levels of 25-hydroxyvitamin D, the major circulating form of the vitamin, declined in all subjects and to below normal range in six (P less than 0.01). Parathyroid hormone levels rose by 36% (P less than 0.01) in response to the relative hypocalcemia produced. Isoniazid inhibited hepatic mixed-function oxidase activity, as evidenced by a reduction in antipyrine and cortisol oxidation, and a similar inhibition of the hepatic 25-hydroxylase and renal 1 alpha-hydroxylase would explain the reduction in the corresponding vitamin D metabolites. This perturbation of vitamin D metabolism differs from the vitamin D wasting effects after rifampicin. Patients with tuberculosis treated with isoniazid and rifampicin may show changes similar to those shown here in calcium and phosphate homeostasis and thus may be at risk of developing metabolic bone disorders.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7273600     DOI: 10.1038/clpt.1981.173

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  18 in total

Review 1.  New antituberculous drugs in development.

Authors:  Umesh G Lalloo; Anish Ambaram
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

2.  Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A.

Authors:  Z Desta; N V Soukhova; D A Flockhart
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

3.  Lowering of theophylline clearance by isoniazid in slow and rapid acetylators.

Authors:  B Santoso
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

Review 4.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 5.  Calcium and vitamin D metabolism in granulomatous diseases.

Authors:  M Fuss; T Pepersack; C Gillet; R Karmali; J Corvilain
Journal:  Clin Rheumatol       Date:  1992-03       Impact factor: 2.980

Review 6.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

Review 7.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

8.  Calcium metabolism during rifampicin and isoniazid therapy for tuberculosis.

Authors:  M J Brodie; C J Hillyard
Journal:  J R Soc Med       Date:  1982-11       Impact factor: 5.344

9.  Influence of rifampicin treatment on antipyrine clearance and metabolite formation in patients with tuberculosis.

Authors:  M W Teunissen; W Bakker; J E Meerburg-Van der Torren; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1984-11       Impact factor: 4.335

Review 10.  Drug-vitamin D interactions: a systematic review of the literature.

Authors:  Kim Robien; Sarah J Oppeneer; Julia A Kelly; Jill M Hamilton-Reeves
Journal:  Nutr Clin Pract       Date:  2013-01-10       Impact factor: 3.080

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.